摘要
目的:探讨IL-4、IL-6、IL-10和TNF-α基因多态性与药物性肝损伤(drug-induced liver injury,DILI)易感性关系。方法:检索Pubmed、Web of Science、Cochrane Library、EMBASE、知网与万方数据库,查找建库有关IL-4、IL-6、IL-10和TNF-α基因多态性与DILI发病风险的文献。应用STATA12.0对数据进行Meta分析。结果:共纳入10篇文献,共包括717例DILI患者和1 674例正常对照。所有研究都纳入Meta分析发现IL-6 rs1800796G>C中G等位基因携带者(OR=2.507, 95%CI[1.542, 4.074],P=0.000)患DILI的风险显著升高,而TNF-αrs1800629G>A中G等位基因携带者(OR=0.715, 95%CI[0.524, 0.976],P=0.035)患DILI的风险显著降低。在剔除一项显著的异质性研究后,携带IL-6 rs2066992G>T中G等位基因人群(OR=2.465, 95%CI[1.506, 4.036],P=0.000)人群患DILI风险显著增加,而携带IL-10 rs1800872A>C中C等位基因(OR=0.818, 95%CI[0.679, 0.985],P=0.034)人群患DILI风险则显著降低。本研究暂未发现IL-4各基因位点基因型与DILI有明显关联性。结论:TNF-α(rs1800629G>A)、IL-6(rs1800796G>C、rs2066992G>T)与IL-10(rs1800872A>C)与DILI发生有一定的关联性。
OBJECTIVE To investigate the relationship between the polymorphisms of IL-4, IL-6, IL-10 and TNF-α genes and the susceptibility of drug-induced liver injury(DILI).METHODS The PubMed, Web of Science, Cochrane Library, EMBASE, CNKI and Wanfang databases were searched to identify the literatures about IL-4, IL-6, IL-10 and TNF-α gene polymorphism and the risk of DILI. Meta-analysis was performed with Stata 12.0.RESULTS A total of 10 articles were included, including 717 DILI patients and 1674 normal controls. All the studies involved in meta-analysis showed that the risk of DILI in IL-6 rs1800796 G>C(OR=2.507, 95% CI [1.542, 4.074], P=0.000) was significantly higher, while the risk of DILI in TNF-α rs1800629 G>A(OR=0.715, 95% CI [0.524, 0.976], P=0.035) was significantly lower. After eliminating a significant heterogeneity study, the risk of DILI was significantly increased in the population with G allele in IL-6 rs2066992 G>T(OR=2.465, 95% CI [1.506, 4.036], P=0.000), while the risk of DILI was significantly reduced in the population with C allele in IL-10 rs1800872 A>C(OR=0.818, 95% CI [0.679, 0.985], P=0.034). In this study, there was no significant correlation between IL-4 genotypes and DILI.CONCLUSION TNF-α rs1800629 G>A, IL-6 rs1800796 G>C, rs2066992 G>T, IL-10 rs1800872 A>C are assiociated with the risk of DILI.
作者
焦红军
张明亮
李伟霞
王晓艳
张辉
陈盼盼
唐进法
JIAO Hong-jun;ZHANG Ming-liang;LI Wei-xia;WANG Xiao-yan;ZHANG Hui;CHEN Panpan;TANG Jin-fa(College of Pharmacy,The Second Affiliated Hospital of Zhengzhou University,Henan Zhengzhou 450014,China;Henan Province En ineering Laboratory for Clinical Evaluation Technology of Chinese Medicine,Departmentof Pharmacy,The First Affiliated Hospital of Henan University of Chinese Medicine,Henan Zhengzhou 45000,China;Collaborative Innovation Center for Respiratory Diseas Diagnosis and Treatment&Chinese Medicine,Henan University of Chinese Medicine,Henan Zhengzhou 450046,China)
出处
《中国医院药学杂志》
CAS
北大核心
2020年第13期1462-1466,1470,共6页
Chinese Journal of Hospital Pharmacy
基金
河南省科技攻关项目(编号:18210241008)
河南省中医药科学研究专项(编号:2017ZY2046、2019ZYBJ08)
河南省中医药拔尖人才培养项目。
